Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Herrmann

Showing results (51-60 of 470) with videos related to

Pageof 47
Sort By:
Experimental Neurology|June 12, 2008
Commentary: Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levelsKrista L Lanctôt, Nathan Herrmann, Lana S Rothenburg
International Psychogeriatrics|July 28, 2006
Behavioral correlates of GABAergic disruption in Alzheimer's diseaseKrista L Lanctôt, Nathan Herrmann, Lana Rothenburg, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|February 24, 2015
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsColleen J Maxwell, Kathryn Stock, Dallas Seitz, et al.
The Journal of Clinical Psychiatry|December 10, 2015
Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trialsJordana O'Regan, Krista L Lanctôt, Graham Mazereeuw, et al.
The European Journal of Neuroscience|May 12, 2017
The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: a meta-analysisAdam Dinoff, Nathan Herrmann, Walter Swardfager, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|July 16, 2015
Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID)Nathan Herrmann, Tetsuhiro Harimoto, Robert Balshaw, et al.
The Journal of Clinical Psychiatry|February 13, 2019
Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-AnalysisMyuri Ruthirakuhan, Krista L Lanctôt, Danielle Vieira, et al.
The Journal of Clinical Psychiatry|December 15, 2018
Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk FactorsDamien Gallagher, Alex Kiss, Krista L Lanctot, et al.
CNS Drugs|October 12, 2010
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's diseaseJaclyn Cappell, Nathan Herrmann, Stephen Cornish, et al.
International Psychogeriatrics|March 12, 2013
A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's diseaseNathan Herrmann, Serge Gauthier, Neli Boneva, et al.
Pageof 47

Showing results (51-60 of 470) with videos related to

Sort By:
Pageof 47
Experimental Neurology|June 12, 2008
Commentary: Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levelsKrista L Lanctôt, Nathan Herrmann, Lana S Rothenburg
International Psychogeriatrics|July 28, 2006
Behavioral correlates of GABAergic disruption in Alzheimer's diseaseKrista L Lanctôt, Nathan Herrmann, Lana Rothenburg, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|February 24, 2015
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsColleen J Maxwell, Kathryn Stock, Dallas Seitz, et al.
The Journal of Clinical Psychiatry|December 10, 2015
Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trialsJordana O'Regan, Krista L Lanctôt, Graham Mazereeuw, et al.
The European Journal of Neuroscience|May 12, 2017
The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: a meta-analysisAdam Dinoff, Nathan Herrmann, Walter Swardfager, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|July 16, 2015
Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID)Nathan Herrmann, Tetsuhiro Harimoto, Robert Balshaw, et al.
The Journal of Clinical Psychiatry|February 13, 2019
Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-AnalysisMyuri Ruthirakuhan, Krista L Lanctôt, Danielle Vieira, et al.
The Journal of Clinical Psychiatry|December 15, 2018
Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk FactorsDamien Gallagher, Alex Kiss, Krista L Lanctot, et al.
CNS Drugs|October 12, 2010
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's diseaseJaclyn Cappell, Nathan Herrmann, Stephen Cornish, et al.
International Psychogeriatrics|March 12, 2013
A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's diseaseNathan Herrmann, Serge Gauthier, Neli Boneva, et al.
Pageof 47